Reported Earnings • Apr 16
Full year 2025 earnings released: NT$0.60 loss per share (vs NT$0.59 loss in FY 2024) Full year 2025 results: NT$0.60 loss per share (further deteriorated from NT$0.59 loss in FY 2024). Revenue: NT$127.1m (flat on FY 2024). Net loss: NT$62.5m (loss widened 1.4% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year. 공시 • Mar 27
PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026 PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$153m revenue, or US$4.9m). Market cap is less than US$100m (NT$848.9m market cap, or US$27.1m). New Risk • Jan 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (NT$153m revenue, or US$4.8m). Market cap is less than US$100m (NT$959.8m market cap, or US$30.3m). New Risk • Jul 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (NT$128m revenue, or US$4.4m). Market cap is less than US$100m (NT$1.04b market cap, or US$35.5m). 공시 • Mar 25
PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025 PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city Taiwan New Risk • Mar 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.1m). Market cap is less than US$100m (NT$1.17b market cap, or US$35.6m). New Risk • Dec 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.2m). Market cap is less than US$100m (NT$1.22b market cap, or US$37.4m). Reported Earnings • Apr 27
Full year 2023 earnings released: NT$0.56 loss per share (vs NT$0.51 loss in FY 2022) Full year 2023 results: NT$0.56 loss per share (further deteriorated from NT$0.51 loss in FY 2022). Revenue: NT$167.2m (down 13% from FY 2022). Net loss: NT$58.5m (loss widened 10% from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. 공시 • Mar 30
PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024 PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.40b market cap, or US$44.4m). New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (NT$1.43b market cap, or US$45.4m). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 19
First half 2022 earnings released: EPS: NT$0 (vs NT$0.57 loss in 1H 2021) First half 2022 results: EPS: NT$0 (up from NT$0.57 loss in 1H 2021). Revenue: NT$108.1m (up 55% from 1H 2021). Net loss: NT$30.9m (loss narrowed 48% from 1H 2021). Reported Earnings • May 02
Full year 2021 earnings released: NT$1.27 loss per share (vs NT$1.37 loss in FY 2020) Full year 2021 results: NT$1.27 loss per share (up from NT$1.37 loss in FY 2020). Revenue: NT$124.9m (up 23% from FY 2020). Net loss: NT$131.6m (loss narrowed 6.7% from FY 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 04
PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022 PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022. Reported Earnings • Apr 28
Full year 2020 earnings released: NT$1.37 loss per share (vs NT$2.32 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$101.3m (up 42% from FY 2019). Net loss: NT$141.1m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 18
New 90-day low: NT$20.10 The company is down 22% from its price of NT$25.70 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: NT$20.45 The company is down 51% from its price of NT$41.50 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: NT$25.40 The company is down 61% from its price of NT$65.60 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 9.0% over the same period. Is New 90 Day High Low • Oct 13
New 90-day low: NT$28.55 The company is down 52% from its price of NT$59.90 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: NT$37.45 The company is down 46% from its price of NT$69.80 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 14% over the same period.